Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 8, 2020, Pages

  Murray, Alistair ^a   Nguyen, Tran M ^b   Parker, Claire E ^b   Feagan, Brian G ^b,c   MacDonald, John K ^c  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; DIVISTYRAMINE; MESALAZINE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL ABSCESS; ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE PANCREATITIS; ANOREXIA; CARCINOMA; COLONOSCOPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHEMA; ERYTHEMA NODOSUM; EVIDENCE BASED MEDICINE; FEVER; FLATULENCE; GASTROINTESTINAL SYMPTOM; GENERAL CONDITION IMPROVEMENT; HEADACHE; HEPATITIS; HUMAN; INGUINAL HERNIA; INTENTION TO TREAT ANALYSIS; LOSS OF APPETITE; MALAISE; MEASLES; NAUSEA; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; POLYURIA; PRIORITY JOURNAL; RASH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VEIN THROMBOSIS; VOMITING; DRUG ADMINISTRATION; INDUCTION CHEMOTHERAPY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATIENT DROPOUT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL BIAS; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIAS; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDUCTION CHEMOTHERAPY; MESALAMINE; PATIENT DROPOUTS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SULFASALAZINE; TREATMENT FAILURE;

EID: 85089407876     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000543.pub5     Document Type: Review

References (179)

1. Andreoli A, Cosintino R, Trotti R, Berri F, Prantera C. 5-aminosalicylic acid versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. In: Clinical Controversies in Inflammatory Bowel Disease. 1987:170. x-wiley/crsRef/14280231
2. Bresci G, Carrai M, Venturini G, Gambardella L. Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity. International Journal of Tissue Reactions 1990;12(4):243-6. x-wiley/crsRef/14280233
3. Cai JT, Wu LF, Du Q, Qian KD. Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: randomized controlled clinical trial. Chinese Journal of Digestion 2001;21(10):593-5. x-wiley/crsRef/14280235
4. D'Haens G, Hommes D, Engels L, Baert F, Van der Waaij L, Connor P, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Alimentary Pharmacology and Therapeutics 2006;24(7):1087-97. x-wiley/crsRef/14280237
5. D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology & Therapeutics 2017;46(3):292-302. x-wiley/crsRef/14280239
6. Ewe K, Eckhardt V, Kanzler G. Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology 1988;23(Suppl 148):70-5. x-wiley/crsRef/14280241
7. Farup PG, Hinterleitner TA, Lukás M, Hébuterne X, Rachmilewitz D, Campieri M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases 2001;7(3):237-42. x-wiley/crsRef/14280243
8. Farup PG, Oddsson E, Hinterleitner T. Mesalamine 4 g prolonged release granules BID and QID versus tablets QID for mild/moderate UC. Gastroenterology 1999;116(4 Part 2):A713. x-wiley/crsRef/14280244
9. Feagan B, Sandborn W, D'Haens G, McDonald J, Rutgeerts P, Munkholm P, et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology 2012;107:S579-80. x-wiley/crsRef/14280246
10. Feagan BG, Sandborn WJ, D’Haens G, Pola S, McDonald JW, Rutgeerts P, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145(1):149-57. x-wiley/crsRef/14280247
11. Feurle GE, Theuer D, Velasco S, Barry BA, Wordehoff D, Sommer A, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut 1989;30(10):1354-61. x-wiley/crsRef/14280249
12. Feurle GE, Theuer D, Velasco S, Barry BA, Wordehoff D, Sommer A, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology 1988;94(5 Part 2):A126. x-wiley/crsRef/14280250
13. Fleig WE, Laudage G, Sommer H, Wellman W, Stange EF, Riemann J. Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion 1988;40(3):173-80. x-wiley/crsRef/14280252
14. Flourié B, Hagège H, Tucat G, Maetz D, Hébuterne X, Kuyvenhoven JP, et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2013;37(8):767-75. x-wiley/crsRef/14280254
15. Flourié B, Hagège H, Tucat G, Masclee A, Dewit O, Probert C, et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's & Colitis 2012;6:S82. x-wiley/crsRef/14280255
16. Flourié B, Hagège H, Tucat G, Masclee A, Dewit O, Probert C, et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology 2012;142(5 suppl 1):S197. x-wiley/crsRef/14280256
17. Flourié B, Kuyvenhoven J, Probert C, Dewit O. Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's & Colitis 2013;7:S236. x-wiley/crsRef/14280257
18. Pierik M, Hagège H, Tucat G, Masclee A, Dewit O, Probert C, et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's & Colitis 2012;6:S82-3. x-wiley/crsRef/14280258
19. Forbes A, Al-Damluji A, Ashworth S, Bramble M, Herbert K, Ho J, et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Alimentary Pharmacology & Therapeutics 2005;21(9):1099-104. x-wiley/crsRef/14280260
20. Gibson PR, Fixa B, Pekárková B, Bátovský M, Radford-Smith G, Tibitanzl J, et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2006;23(7):1017-26. x-wiley/crsRef/14280262
21. Good L, Nester T, Borgen L. A double-blind comparison of controlled release mesalamine tablets and sulfasalazine in the treatment of ulcerative colitis. Gastroenterology 1992;102:A630. x-wiley/crsRef/14280264
22. Green JR, Holdsworth CD, Lobo AJ, Leicester R, Gibson JA, Kerr GD, et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis. In: Digestive Disease Week Abstract Book. 1997. x-wiley/crsRef/14280266
23. Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology 1998;114(1):15-22. x-wiley/crsRef/14280267
24. Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2002;16(1):61-8. x-wiley/crsRef/14280269
25. Green JR, Swan CH, Rowlinson AE, Gibson JA, Brown P, Kerr GD, et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology 1993;104(4 Part 2):709. x-wiley/crsRef/14280270
26. Hanauer S, Beshears L, Wilkinson C. Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology 1990;98(5 Part 2):A174. x-wiley/crsRef/14280272
27. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. American Journal of Gastroenterology 1993;88(8):1188-97. x-wiley/crsRef/14280273
28. Hanauer S, Schwartz J, Roufail W, Robinson M, Cello J, Safdi M, et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology 1989;96:A195. x-wiley/crsRef/14280274
29. Miner P, Nostrant T, Wruble L, Hines C, Johnson S, Wilkinson C, et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology 1991;100(5 Part 2):A231. x-wiley/crsRef/14280275
30. Robinson M, Cello J, Safdi M, Schwartz J, Roufail W, Hoop R, et al. Mesalamine (Pentasa) enhances quality of life (QofL) for ulcerative colitis (UC) patients. Gastroenterology 1991;100(5 Part 2):A243. x-wiley/crsRef/14280276
31. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology & Therapeutics 1994;8(1):27-34. x-wiley/crsRef/14280277
32. Hanauer SB, Barish C, Pambianco D, Sigmon R, Gannan R, Koval G, et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology 1996;110:A921. x-wiley/crsRef/14280279
33. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology 2005;100(11):2478-85. x-wiley/crsRef/14280281
34. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology 2007;21(12):827-34. x-wiley/crsRef/14280283
35. Hetzel DJ, Bochner F, Imhoff DM, Gibson GE, Fitch RJ, Hecker R, et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology 1985;88:A1418. x-wiley/crsRef/14280285
36. Hetzel DJ, Shearman DJ, Bochner F, Imhoff DM, Gibson GE, Fitch RJ, et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology 1986;1:257-66. x-wiley/crsRef/14280286
37. Hetzel DJ, Shearman DJ, Labrooy J, Bochner F, Imhoff DM, Gibson GE, et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement 1988;23(148):61-9. x-wiley/crsRef/14280287
38. Hiwatashi N, Suzuki Y, Mitsuyama K, Munakata A, Hibi T. Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology 2011;46(1):46-56. x-wiley/crsRef/14280289
39. Ito H, Iida M, Matsumoto T, Suzuki Y, Koyama H, Yoshida T, et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology 2010;1:S166. x-wiley/crsRef/14280291
40. Ito H, Iida M, Matsumoto T, Suzuki Y, Sasaki H, Yoshida T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases 2010;16(9):1567-74. x-wiley/crsRef/14280292
41. Jiang XL, Cui HF. Different therapy for different types of ulcerative colitis. World Journal of Gastroenterology 2004;10(10):1513-20. x-wiley/crsRef/14280294
42. Hanauer S, Sandborn W, Lichtenstein G, Kamm M, Barrett K, Joseph R. MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases 2007;13(S5):663. x-wiley/crsRef/14280296
43. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132(1):66-75. x-wiley/crsRef/14280297
44. Kruis W, Brandes JW, Schreiber S, Theuer D, Krakamp B, Schutz E, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology & Therapeutics 1998;12(8):707-15. x-wiley/crsRef/14280299
45. Kruis W, Schreiber S, Theuer D, Schutz E, Krakamp B, Otto P, et al. Comparison of an azoboundamino salicylate (olsalazine) vs. a coated aminosalicylate (mesalamine) for active ulcerative colitis. Gastroenterology 1996;110(4):942. x-wiley/crsRef/14280300
46. Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology 2003;1(1):36-43. x-wiley/crsRef/14280302
47. Kruis W, Meir SB, Feher J, Stolte M. Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology 2000;118(4 Suppl 2):A780. x-wiley/crsRef/14280303
48. Kruis W, Gorelov A, Kiudelis G, Rácz I, Pokrotnieks J, Horynski M, et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology 2007;132(4 Suppl 1):A130-1. x-wiley/crsRef/14280305
49. Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009;58(2):233-40. x-wiley/crsRef/14280306
50. Levine DS, Pruitt R, Riff D, Koval G, Sales D, Wruble L, et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology 1997;112:A1026. x-wiley/crsRef/14280308
51. Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology 2002;97(6):1398-407. x-wiley/crsRef/14280309
52. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology 2007;5(1):95-102. x-wiley/crsRef/14280311
53. Maier K, Fruhmorgen P, Bode JC, Heller T, Von Gaisberg U, Klotz U. Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid [Erfolgreiche akutbehandlung chronisch-entzundlicher darmerkrankungen mit oraler 5-aminosalicylsaure]. Deutsche Medizinische Wochenschrift 1985;110(10):363-8. x-wiley/crsRef/14280313
54. Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics 2002;16(1):69-77. x-wiley/crsRef/14280315
55. Marakhouski Y, Fixa B, Holoman J, Hulek P, Lukas M, Batovsky M, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2005;21(2):133-40. x-wiley/crsRef/14280317
56. Marakhouski Y, Fixa B, Holoman J. Erratum: a double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2005;21(6):793. x-wiley/crsRef/14280318
57. Miglioli M, Bianchi Porro G, Brunetti G, Sturniolo GC, and the Italian IBD group. Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. European Journal of Gastroenterology and Hepatology 1990;2:229-34. x-wiley/crsRef/14280320
58. Miglioli M, Brunetti G, Sturniolo GC, Bianchi Porro G, Campieri M, Cottone M, et al. Oral 5-ASA (Asacol) in mild ulcerative colitis. a randomized double blind dose ranging trial. Italian Journal of Gastroenterology 1989;21(1 Suppl):7-8. x-wiley/crsRef/14280321
59. Mihas AA, Xynopoulos D, Mihas TA. A prospective trial of oral 5-aminosalicylic acid vs sulfasalazine in ulcerative colitis. Gastroenterology 1988;94(5 Part 2):A303. x-wiley/crsRef/14280323
60. Munakata A, Yoshida Y, Muto T, Tsuchiya S, Fukushima T, Hiwatashi N, et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Journal of Gastroenterology 1995;30(Suppl 8):108-11. x-wiley/crsRef/14280325
61. Munakata A, Yoshida Y, Muto T. Clinical efficacy of oral controlled-release mesalazine, N-5ASA on ulcerative colitis: double-blind comparative study in comparison with salazosulphapyridineu. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics) 1994;22(Suppl 10):S2555-83. x-wiley/crsRef/14280326
62. Pontes C, Vives R, Torres F, Panes J. Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflammatory Bowel Diseases 2014;20(11):2004-12. x-wiley/crsRef/14280328
63. Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology 2002;97(12):3078-86. x-wiley/crsRef/14280330
64. Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson JF, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology 2000;118(4 Suppl 2):A120-1. x-wiley/crsRef/14280331
65. Pruitt RE, Rosen AA, Wruble LD, Sedghi S, Shepard RD, Mareya SM. Safety and tolerability of twice-daily balsalazide tablets: Results from 2 randomized, double-blind, multicenter, phase 3 studies and 1 open-label, multicenter, phase 3 study. Gastroenterology 2009;136(5 Suppl 1):A523. x-wiley/crsRef/14280332
66. Qian LP, Lin GJ, Xu SR, Ding WQ. Clinical effect of olsalazine sodium capsule in the treatment of ulcerative colitis. Fudan University Journal of Medical Sciences 2004;31(4):421-4. x-wiley/crsRef/14280334
67. Rachmelewitz D. Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology 1988;94(5 Part 2):A362. x-wiley/crsRef/14280336
68. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298(6666):82-6. x-wiley/crsRef/14280337
69. Behrens C, Bias P, Malchow H, Raedler A. Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology 2003;124(4 Suppl 1):A379. x-wiley/crsRef/14280339
70. Raedler A, Behrens C, Bias P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis -- results from a randomized-controlled trial. Alimentary Pharmacology & Therapeutics 2004;20(11-12):1353-63. x-wiley/crsRef/14280340
71. Rao SS, Dundas SA, Holdsworth CD, Cann PA, Palmer KR, Corbett CL. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut 1989;30(5):675-9. x-wiley/crsRef/14280342
72. Rao SS, Holdsworth CD, Palmer KL, Cann PA, Dundas SA, Corbett CL. Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut 1988;29:A705. x-wiley/crsRef/14280343
73. Rijk MCM, Tongerson JH. The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology 1991;100:A243. x-wiley/crsRef/14280345
74. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg A. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988;29(5):669-74. x-wiley/crsRef/14280347
75. Riley SA, Mani V, Goodman MJ, Turnberg LA. Delayed-release 5-aminosalicylic acid (5-ASA) and sulphasalazine (SSZ) in the treatment of mild to moderate ulcerative colitis (UC) relapse. Gut 1987;28:A1329. x-wiley/crsRef/14280348
76. Robinson M, Gitnick G, Balart L, Das K, Turkin D. Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology 1988;84:A381. x-wiley/crsRef/14280350
77. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology & Therapeutics 1994;8(1):27-34. x-wiley/crsRef/14280351
78. Sandborn WJ, Regula J, Feagan B, Belousova EA, Jojic NV, Lukas M, et al. Efficacy and safety of delayed-release oral mesalamine at 4.8g/d (800mg tablet) in the treatment of moderately active ulcerative colitis: results of the ASCEND III study. Gastroenterology 2008;134(4 Suppl 1):A99. x-wiley/crsRef/14280353
79. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009;137(6):1934-43. x-wiley/crsRef/14280354
80. Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143(5):1218-26. x-wiley/crsRef/14280356
81. Pruitt RE, Rosen AA, Wruble L, Sedghi S, Shepard RD, Mareya SM, et al. Safety and tolerability of twice-daily balsalazide tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology 2008;134(4 Suppl 1):A494. x-wiley/crsRef/14280358
82. Rubin DT, Rosen AA, Sedghi S, Shepard RD, Mareya SM, Huang S, et al. Twice-daily balsalazide tablets improve patient quality of life after 2 and 8 weeks of treatment: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology 2008;134(4 Suppl 1):A494. x-wiley/crsRef/14280359
83. Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology 2009;104(6):1452-9. x-wiley/crsRef/14280360
84. Scherl EJ, Pruitt RE, Gordon GL, Lamet M, Shaw AL, Huang S, et al. Twice-daily dosing of balsalazide tablets 3.3 g is safe and effective in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology 2009;1:A520. x-wiley/crsRef/14280361
85. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine 1987;317(26):1625-9. x-wiley/crsRef/14280363
86. Sninsky CA, Cort DH, Shanahan F, Powers BJ, Sessions JT, Pruitt RE, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine 1991;115(5):350-5. x-wiley/crsRef/14280365
87. Sutherland LR, Robinson M, Onstad G, Peppercorn M, Greenberger N, Goodman M, et al. A double-blind, placebo-controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Canadian Journal of Gastroenterology 1990;4:463-7. x-wiley/crsRef/14280367
88. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Elisei W. Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Gastroenterology 2005;128((4 Suppl 2)):A17. x-wiley/crsRef/14280369
89. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor 2004;10(11):126-31. x-wiley/crsRef/14280370
90. Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB. Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology 1988;148:40-4. x-wiley/crsRef/14280372
91. Zinberg J, Molinas S, Das KM. A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology 1987;92:A1711. x-wiley/crsRef/14280374
92. Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology 1990;85(5):562-6. x-wiley/crsRef/14280375
93. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55(1):47-53. x-wiley/crsRef/14280377
94. Ahluwalia NK, Thompson DG, Goodman MJ, Mani V, McIntyre J, Dane G. Double-blind randomized trial of 4.8 g vs. 2.4 g of mesalazine for 4 weeks in the treatment of acute ulcerative colitis. Gastroenterology 1992;102:A588. x-wiley/crsRef/14280379
95. Behrens C, Bias P, Malchow H, Raedler A. Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology 2013;124(4 Suppl 1):A379. x-wiley/crsRef/14280381
96. Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Dorova J, et al. Efficacy and safety of novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterology Journal 2018;6(1):138-47. x-wiley/crsRef/14280383
97. Fiorino G, Sturniolo GC, Bossa F, Cassinotti A, Sabatino AD, Giuffrida P, et al. A phase 2a, multicenter, randomized, double-blind,parallel-group, placebo-controlled trial of IBD98-M delayed-release capsules to induce remission in patients with active and mild to moderate ulcerative colitis. Cells 2019;8(6):1-11. x-wiley/crsRef/14280385
98. Gross V, Bunganic I, Belousova EA, Mikhailova TL, Kupcinskas L, Kiudelis G, et al. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. Journal of Crohn's & Colitis 2011;5(2):129-38. x-wiley/crsRef/14280387
99. Irvine EJ, Yeh CH, Ramsey D, Stirling AL, Higgins PD. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2008;28(11-12):1278-86. x-wiley/crsRef/14280389
100. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases 2009;15(1):1-8. x-wiley/crsRef/14280391
101. Levine A, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, et al. Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral Mesalamine: A prospective cohort study. Journal of Pediatric Gastroenterology and Nutrition 2017;64(Suppl 1):49. x-wiley/crsRef/14280393
102. Levine A, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, et al. Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: A prospective cohort study. Journal of Crohn's & Colitis 2017;11(Suppl 1):S285. x-wiley/crsRef/14280394
103. Mahmood A, Melley L, Fitzgerald AJ, Ghosh S, Playford RJ. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Alimentary Pharmacology & Therapeutics 2005;21(11):1357-64. x-wiley/crsRef/14280396
104. Paoluzi P, D'Albasio G, Pera A, Bianchi Porro G, Paoluzi OA, Pica R, et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Digestive and Liver Disease 2002;34(11):787-93. x-wiley/crsRef/14280398
105. Park SK, Eun CS, Seo GS, Lim J, Kim TO, Park DI. The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's & Colitis 2018;12(Suppl 1):S367. x-wiley/crsRef/14280400
106. Pruitt RE, Gremillion DE, Herring RW, Bailey AH, Faust TW, Potter M, et al. Oral Asacol in the treatment of mild to moderate ulcerative colitis: the Nashville experience. Journal of the Tennessee Medical Association 1991;84(5):237. x-wiley/crsRef/14280402
107. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, et al. Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: A randomised, placebo-controlled trial. Journal of Crohn's & Colitis 2017;11(7):785-91. x-wiley/crsRef/14280404
108. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. American Journal of Gastroenterology 1997;92(10):1867-71. x-wiley/crsRef/14280406
109. Suzuki Y, Iida M, Ito H, Nishino H, Ohmori T, Arai T, et al. 2.4 g Mesalamine (Asacol 400 mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: A randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases 2017;23(5):822-32. x-wiley/crsRef/14280408
110. Turner D, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, et al. Once- versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: A randomised controlled trial. Journal of Crohn's & Colitis 2017;11(5):527-33. x-wiley/crsRef/14280410
111. Vecchi M, Meucci G, Gionchetti P, Beltrami M, Di Maurizio P, Beretta L, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: A double-blind, double-dummy, randomized multicentre study. Alimentary Pharmacology & Therapeutics 2001;15(2):251-6. x-wiley/crsRef/14280412
112. Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Digestive Diseases and Sciences 2000;45(5):976-81. x-wiley/crsRef/14280414
113. Ye LN, Huang YB, Chen CX, Lv W, Fan YH, Yang HH, et al. Combined oral and suppository treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with mild/moderate extensive or left-sided active ulcerative colitis: a randomized multi-center controlled study. Journal of Digestive Diseases 2018;19(1):35. x-wiley/crsRef/14280416
114. Yoshimura N, Okano S, Sako M, Takazoe M. Efficacy of once a day multi matrix mesalamine formulation, lialda in patients with active mild to moderate ulcerative colitis after inadequate response to the pH-dependent release mesalamine formulation, asacol. Journal of Crohn's & Colitis 2018;12(1):S300. x-wiley/crsRef/14280418
115. NCT02522767. Mesalamine 4 g sachet for the induction of remission in active, mild to moderate ulcerative colitis (UC) (Ferring Pharmaceuticals). clinicaltrials.gov/show/NCT02522767 (first received 13 August 2015). x-wiley/crsRef/14280420
116. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? New England Journal of Medicine 1995;332(17):1125-31.
117. Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report and literature review. Pediatric Nephrology 2004;19(5):550-3.
118. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977;2(8044):892-5.
119. Beaulieu DB, Schwartz DA. Medication persistence in patients with ulcerative colitis: meeting the challenges and improving patient outcomes. Medscape CME Gastroenterology 2009. Available from www.medscape.org/viewarticle/713895.
120. Brixner D, Magowan S, Accortt N. Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. In: Academy of Managed Care Pharmacy Annual Meeting. San Diego, CA, 2007.
121. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Digestive Diseases and Sciences 1983;28(7):609-15.
122. Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmunity Reviews 2014;13(4-5):463-6.
123. Danese S, Fiocchi C. Ulcerative colitis. New England Journal of Medicine 2011;365(18):1713-25.
124. Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. New England Journal of Medicine 1973;289(10):491-5.
125. Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. British Journal of Clinical Pharmacology 1982;14(3):405-8.
126. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964;5(5):437-42.
127. Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, et al. Predictors of medication adherence in inflammatory bowel disease. American Journal of Gastroenterology 2007;102(7):1417-26.
128. Elseviers MM, D'Haens G, Lerebours E, Plane C, Stolear JC, Riegler G, et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clinical Nephrology 2004;61(2):83-9.
129. Feuerstein JD, Cheifetz AS. Ulcerative colitis. Mayo Clinic Proceedings 2014;89(11):1553-63.
130. Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology 2011;106(4):601-16.
131. Frandsen NE, Saugmann S, Marcussen N. Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron 2002;92(1):200-2.
132. Greenfield SM, Punchard NA, Teare JP, Thompson RP. Review article: The mode of action of the aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 1993;7(4):369-83.
133. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
134. Hardy JG, Healey JN, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 1987;1(4):273-80.
135. Hayllar J, Bjarnason I. Sulphasalazine in ulcerative colitis: In memoriam? Gut 1991;32(5):462-3.
136. Higgins JP, Thompson SG, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60.
137. Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
138. Ireland A, Jewell DP. Olsalazine in patients intolerant of sulphasalazine. Scandinavian Journal of Gastroenterology 1987;22(9):1038-40.
139. Järnerot G. Withdrawal rates because of diarrhea in Dipentum-treated patients with ulcerative colitis are low when Dipentum is taken with food and dose-titrated. Gastroenterology 1996;110:A932.
140. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology 2001;96(10):2929-33.
141. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine 2003;114(1):39-43.
142. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: A systematic review. Reviews in Gastroenterological Disorders 2003;3:210.
143. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacology & Therapeutics 2006;23(5):577-85.
144. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy 2008;14(1 Suppl A):S2-12.
145. Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. New England Journal of Medicine 1980;303(26):1499-502.
146. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. American Journal of Gastroenterology 1999;94(7):1733-42.
147. Loftus EJ. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17.
148. Maeda S, Nomura S, Tahara M, Haneda M, Kikkawa R. Interstitial nephritis after treatment with mesalazine in the patient with ulcerative colitis. Nihon Naika Gakkai Zasshi 2001;90(5):872-3.
149. Magowan S, Kane S, Lange JL. 5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens. American Journal of Gastroenterology 2006;101:S447. Abstract 1144.
150. Misiewitz JJ, Lennard-Jones JE, Connell AM, Baron JH, Jones FA. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8.
151. Myers B, Evans DN, Rhodes J, Evans BK, Hughes BR, Lee MG, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987;28(2):196-200.
152. Nielsen OH. Sulfasalazine intolerance: a retrospective study of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1982;17(3):389-93.
153. Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. British Journal of Clinical Pharmacology 1983;16(6):738-40.
154. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380(9853):1606-19.
155. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. Journal of Pharmacology and Experimental Therapeutics 1972;181(3):555-62.
156. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clinical Epidemiology 2013;5:237-47.
157. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scandinavian Journal of Gastroenterology 1987;22(3):332-6.
158. Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskou S, et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982;83(5):1062-70.
159. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World Journal of Gastroenterology 2006;12(30):4819-31.
160. Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology 2002;97(12):2939-41.
161. Sandborn WJ, Hanauer SB, Buch A. Comparable systemic absorption of 5-ASA and N-AC-5-ASA from U.S. Asacol and Colazal. American Journal of Gastroenterology 2002;97:S263.
162. Sandborn WJ, Hanauer SB. The pharmacokinetic profiles of oral 5ASA formulations used in the management of ulcerative colitis: a systematic review. American Journal of Gastroenterology 2002;97:S269.
163. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics 2003;17(1):29-42.
164. Schroeder H, Campbell DE. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clinical Pharmacology and Therapeutics 1972;13(4):539-51.
165. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). The Cochrane Collaboration, 2019. Available from www.training.cochrane.org/handbook.
166. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2003;18(2):191-8.
167. Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31(11):1271-6.
168. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92(6):1894-8.
169. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No: CD000544. [DOI: 10.1002/14651858.CD000544.pub2]
170. Svartz N. Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Medica Scandinavia 1942;110:557-90.
171. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. British Medical Journal 1955;2(4947):1041-8.
172. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. British Medical Journal 1959;1(5119):387-94.
173. Van Hees PA, Bakker JH, Tongeren JH. Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine. Gut 1980;21(7):632-5.
174. Willoughby CP, Aronson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut 1982;23(12):1081-7.
175. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub3]
176. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine 1993;118:540-9.
177. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflammatory Bowel Diseases 1997;3:65-78.
178. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub2]
179. Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub4]